Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas C A Taylor

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
The American Journal of Gastroenterology|June 16, 2021
Alarming Trends in Opioid Use Among Patients With GERDColin W Howden, Douglas C A Taylor, Joseph Tkacz
The American Journal of Managed Care|February 2, 2002
Use of managed care claims data in the risk assessment of venous thromboembolism in outpatientsMason W Russell, Douglas C A Taylor, Gordon Cummins, et al.
The American Journal of Managed Care|February 2, 2002
Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluationDaniel M Huse, Gordon Cummins, Douglas C A Taylor, et al.
Journal of Medical Economics|July 6, 2012
Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United StatesMyrlene Sanon, Douglas C A Taylor, Anju Parthan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 19, 2008
Budgetary impact of varenicline in smoking cessation in the United KingdomDouglas C A Taylor, Paula Chu, Virginia M Rosen, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|June 18, 2009
Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in CanadaMonika Wagner, Mireille Goetghebeur, Elizabeth Merikle, et al.
Journal of Managed Care Pharmacy : JMCP|August 24, 2010
Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumorsJaime L Rubin, Douglas C A Taylor, Myrlene Sanon, et al.
Pharmacoeconomics|December 14, 2011
Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approachesDouglas C A Taylor, Vivek Pawar, Denise T Kruzikas, et al.
Journal of the American Medical Directors Association|June 12, 2023
The Burden and Treatment of Chronic Constipation Among US Nursing Home ResidentsTingting Zhang, Andrew R Zullo, Hannah O James, et al.
Plos One|January 11, 2021
Lessons learned: Chronic idiopathic constipation patient experiences with over-the-counter medicationsBrian E Lacy, Elizabeth P Shea, Machelle Manuel, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The American Journal of Gastroenterology|June 16, 2021
Alarming Trends in Opioid Use Among Patients With GERDColin W Howden, Douglas C A Taylor, Joseph Tkacz
The American Journal of Managed Care|February 2, 2002
Use of managed care claims data in the risk assessment of venous thromboembolism in outpatientsMason W Russell, Douglas C A Taylor, Gordon Cummins, et al.
The American Journal of Managed Care|February 2, 2002
Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluationDaniel M Huse, Gordon Cummins, Douglas C A Taylor, et al.
Journal of Medical Economics|July 6, 2012
Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United StatesMyrlene Sanon, Douglas C A Taylor, Anju Parthan, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 19, 2008
Budgetary impact of varenicline in smoking cessation in the United KingdomDouglas C A Taylor, Paula Chu, Virginia M Rosen, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|June 18, 2009
Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in CanadaMonika Wagner, Mireille Goetghebeur, Elizabeth Merikle, et al.
Journal of Managed Care Pharmacy : JMCP|August 24, 2010
Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumorsJaime L Rubin, Douglas C A Taylor, Myrlene Sanon, et al.
Pharmacoeconomics|December 14, 2011
Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approachesDouglas C A Taylor, Vivek Pawar, Denise T Kruzikas, et al.
Journal of the American Medical Directors Association|June 12, 2023
The Burden and Treatment of Chronic Constipation Among US Nursing Home ResidentsTingting Zhang, Andrew R Zullo, Hannah O James, et al.
Plos One|January 11, 2021
Lessons learned: Chronic idiopathic constipation patient experiences with over-the-counter medicationsBrian E Lacy, Elizabeth P Shea, Machelle Manuel, et al.
Pageof 3